ACARBOSE 50 MG AND 100 MG TABLETS PL …
PAR Acarbose 50 mg and 100 mg Tablets PL 18909/0126-7 3 ACARBOSE 50 MG AND 100 MG TABLETS PL 18909/0126-7 SCIENTIFIC DISCUSSION TABLE OF CONTENTS
Download ACARBOSE 50 MG AND 100 MG TABLETS PL …
Information
Domain:
Source:
Link to this page:
Documents from same domain
The Human Medicines Regulations 2012 – …
www.mhra.gov.ukThe Human Medicines Regulations 2012 – description of each Part This document provides a brief overview of each Part of the Human Medicines Regulations 2012 …
FULTIUM -D 800 IU CAPSULES - GOV.UK
www.mhra.gov.ukVitamin D deficiency, with levels of 25(OH)D below 25nmol/L (10ng/ml), could result in the disease rickets (or osteomalacia). The disease resulting as a deficiency is considered to be due to malabsorption
GLYCOPYRRONIUM BROMIDE 0.2MG/ML …
www.mhra.gov.ukUKPAR Glycopyrronium Bromide 0.2 mg/ml Solution for Injection PL 00156/0115 1 GLYCOPYRRONIUM BROMIDE 0.2MG/ML SOLUTION FOR INJECTION (PL 00156/0115)
Meloxicam - GOV.UK
www.mhra.gov.ukPL 31388/0003-4 UKPAR Alpex Pharma (UK) Ltd, Meloxicam 7.5mg and 15mg Orodispersible Tablets 3 Scientific Discussion INTRODUCTION Based on the review of the data on quality, safety and efficacy, the UK granted
PL 00010/0643 - GOV.UK
www.mhra.gov.ukUKPAR Canesten HC Cream PL 00010/0643 6 All excipients comply with their respective European Pharmacopoeia monographs, except triceteareth-4-
Public Assessment Report UKPAR Canesten Combi …
www.mhra.gov.ukThis is a summary of the Public Assessment Report (PAR) for Canesten Combi Pessary & External Cream 500mg / 2% w/w pessary & cream (PL 00010/0653).
DCPAR for Ampicillin-Salbactam 1 g--0 5 and 2 g-1 g ...
www.mhra.gov.ukPAR Ampicillin/Sulbactam 1 g/0.5 g and 2 g/1 g powder for Solution for Injection or Infusion UK/H/4322/001-2/DC 1 Public Assessment Report Decentralised Procedure
Public Assessment Report Mutual Recognition …
www.mhra.gov.ukPAR Sayana 104mg/0.65ml Suspension for Injection UK/H/0960/001/MR 1 Public Assessment Report Mutual Recognition Procedure SAYANA 104MG/0.65ML SUSPENSION FOR INJECTION
Cefixime 400 mg Film-coated Tablets, PL 22805 …
www.mhra.gov.ukMHRA PAR; CEFIXIME 400 MG FILM-COATED TABLETS, PL 22805/0032-3 2 Lay summary The Medicines and Healthcare products Regulatory Agency …
Public Assessment Report Decentralised Procedure …
www.mhra.gov.ukPublic Assessment Report Decentralised Procedure LIOTHYRONINE SODIUM 20 MICROGRAM TABLETS (liothyronine sodium) Procedure No: UK/H/6516/001/DC
Related documents
Chronic Complications - World Health Organization
www2.wpro.who.intThe most important chronic complications of type 2 diabetes are those affecting blood vessels and nerves. The microvascular complications (retinopathy, nephropathy and …
Comparison Between Effect of Vildagliptin And …
www.iosrjournals.orgComparison Between Effect of Vildagliptin And Linagliptin on Glycaemic Control… DOI: 10.9790/0853-1609082731 www.iosrjournals.org 28 | Page
Steroid cover for dental patients on long-term …
www.ugr.esPRACTICE BRITISH DENTAL JOURNAL VOLUME 197 NO. 11 DECEMBER 11 2004 681 Steroid cover for dental patients on long-term steroid medication: proposed clinical guidelines based upon a critical review of the literature
Tackling of unhealthy diets, physical inactivity, and ...
www.who.intSeries www.thelancet.com Vol 376 November 20, 2010 1777 disease events. The model accounts for mortality from all causes of death and assumes that mortality rates ...
Name of the Medicine - Baxter Healthcare
www.baxterhealthcare.com.auPRIMENE Product Information Name of the Medicine: Primene 10% (Amino acids Intravenous (IV) Infusion ) Composition: Primene 10% amino acids IV infusion contains essential and nonessential L-amino acids.
GE200 BLOOD GLUCOSE TEST STRIP INSERT - GE …
www.gediabetes.comGE200 BLOOD GLUCOSE TEST STRIP INSERT Intended Use The GE200 Blood Glucose Monitoring Systems is to be used by: - Any person with diabetes, for monitoring their glucose levels in capillary whole blood (CB) from the fingertip, palm and forearm;
Viadur (leuprolide acetate implant) DESCRIPTION
www.accessdata.fda.govViadur® (leuprolide acetate implant) DESCRIPTION . Viadur ® (leuprolide acetate implant) is a sterile nonbiodegradable, osmotically driven miniaturized implant designed to deliver leuprolide acetate for 12 months at a controlled